James Moy to Biomarkers
This is a "connection" page, showing publications James Moy has written about Biomarkers.
Connection Strength
0.548
-
Evaluation of salivary alpha-amylase as a potential biomarker of inhaled ?2-agonist response. Ann Allergy Asthma Immunol. 2023 05; 130(5):664-665.
Score: 0.169
-
PrecISE: Precision Medicine in Severe Asthma: An adaptive platform trial with biomarker ascertainment. J Allergy Clin Immunol. 2021 05; 147(5):1594-1601.
Score: 0.148
-
Glutathione and arginine levels: Predictors for acetaminophen-associated asthma exacerbation? J Allergy Clin Immunol. 2018 07; 142(1):308-311.e9.
Score: 0.120
-
The Precision Interventions for Severe and/or Exacerbation-Prone (PrecISE) Asthma Network: An overview of Network organization, procedures, and interventions. J Allergy Clin Immunol. 2022 02; 149(2):488-516.e9.
Score: 0.039
-
COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions. mBio. 2021 04 20; 12(2).
Score: 0.037
-
The precision interventions for severe and/or exacerbation-prone asthma (PrecISE) adaptive platform trial: statistical considerations. J Biopharm Stat. 2020 11 01; 30(6):1026-1037.
Score: 0.036